Remove Containment Remove Generic Drugs Remove Manufacturing Remove Packaging
article thumbnail

Even Drugs Manufactured in America are not “Made in the USA”

Pharmacy Checkers

One of our more popular Ask PharmacyChecker posts is called “ How can I determine where a drug is manufactured? ” But here’s something different to chew on: Even drugs that our research categorized as manufactured in the U.S. has the pharmaceutical ingredients it needs to make drugs that treat people with Covid-19.

article thumbnail

In the News: September 2021 Regulatory and Development Updates

Camargo

The pilot program is the first step in allowing manufacturers to receive a preliminary review of a novel excipient, prior to drug product formulation. Eligibility for the pilot program has been limited to excipients that 1) have not been previously used in FDA-approved drug products, and 2) do not have an established use in food.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Denies Vanda’s Citizen Petitions Regarding the Need for Braille Labeling for Tasimelteon Generics

FDA Law Blog

Vanda requested that FDA revoke the approval of Apotex’s and Teva’s generic versions of Hetlioz on the grounds that the generic tasimelteon products did not meet the statutory “same labeling” requirement for generic drugs found in 21 U.S.C. § 355(j)(2)(A)(v). FDA regulations, at 21 C.F.R.

article thumbnail

Health Canada’s proposed amendments to the Food and Drug Regulations and the Medical Devices Regulations

Pharma in Brief

Terms and conditions would be imposed after discussions with the manufacturer and would obligate them to take steps to manage risks and resolve uncertainties. An RMP summarizes the risks of a drug and the pharmacovigilance activities and other measures that a manufacturer puts in place to monitor and manage any identified risks.

article thumbnail

In the News: November Regulatory and Development Updates

Camargo

Biopharma and manufacturing company Alkermes was recently able to participate in a remote document review for its ALKS 3831 product. The pharma industry has had meetings with the FDA for new drugs, biologics, and devices for decades. GDUFA has changed this picture, at least for complex drug products.

article thumbnail

Pharma in Brief: The 2021 Year in Review

Pharma in Brief

Meanwhile, the Ontario Superior Court released two decisions dismissing claims made by a generic manufacturer under the Ontario and English Statutes of Monopolies , and common law causes of actions. In 2020, the FC struck down the new price calculation contained in the amendments but upheld the other impugned amendments.

article thumbnail

European Commission vs Big Pharma, or profit vs access?  

Drug Discovery World

Regulatory data protection (RDP) period RDP refers to the time when generic drug makers cannot refer to an innovator drug’s data to obtain a marketing authorisation 2. However, stakeholders should be aware that the leaked review contains no such analysis.